Objectives: Severe alpha 1-antitrypsin (A1AT) deficiency is the one proven genetic risk factor for chronic obstructive pulmonary disease (COPD). Familial aggregation has been demonstrated for COPD among individuals who do not have A1AT deficiency, but linkage analysis of COPD has not been reported. To investigate the optimal phenotype definitions and analytical methods for the linkage analysis of COPD, we examined a set of 28 A1AT- deficient families containing 155 individuals. We have used the protease inhibitor (PI) type as a genetic marker rather than a disease gene, and we have performed linkage analysis between PI type and serum A1AT level and spirometry-related phenotypes. Methods: Linkage analysis was performed on the quantitative phenotypes forced expiratory volume at 1 s (FEV1 as % predicted), the ratio of FEV1 to forced vital capacity (FEV1/FVC as % predicted), and serum A1AT level using the variance component approach in SOLAR, the generalized estimating equation approach in RELPAL, and the model-based classical lod score method in LINKAGE. Linkage analysis with qualitative A1AT and spirometry phenotypes was performed using a model-based method (LINKAGE) and a model-free method (GENEHUNTER). Adjustments for smoking effects were investigated under each method. Results: All of the methods demonstrated linkage of PI type to serum A1AT level. Interestingly, however, the other quantitative phenotypes provided only weak evidence for linkage of PI type to lung disease. Better evidence for linkage of lung disease to PI type was found using a moderate or a mild threshold for the definition of airflow obstruction. Conclusions: For linkage analysis of spirometry phenotypes in A1AT deficiency, qualitative phenotypes provided stronger evidence for linkage than quantitative phenotypes. Possible contributors to the stronger evidence for linkage to qualitative spirometry phenotypes include the ascertainment scheme and the nonnormality of the pulmonary function data in PI Z subjects. This study provides guidelines for studies of the genetics of COPD unrelated to A1AT deficiency.

Keywords:
Linkage analysis, COPD, Genetics, Alpha 1-antitrypsin, Complex diseases
1.
Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994;265:2037–2048.
2.
Davis RM, Novotny TE: Changes in risk factors: The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S82–S84.
3.
Hoyert DL, Kochanek KD, Murphy SL, and Division of Vital Statistics: Deaths: Final data for 1997. National Vital Statist Rep 1999;47:1–104.
4.
Laurell CB, Eriksson S: The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15:132–140.
5.
Lai EC, Kao FT, Law ML, Woo SL: Assignment of the alpha 1-antitrypsin gene and a sequence-related gene to human chromosome 14 by molecular hybridization. Am J Hum Genet 1983;35:385–392.
6.
Yamamoto Y, Sawa R, Okamoto N, Matsui A, Yanagisawa M, Ikemoto S: Deletion 14q(q24.3 to q32.1) syndrome: Significance of peculiar facial appearance in its diagnosis, and deletion mapping of Pi (alpha 1-antitrypsin). Hum Genet 1986;74:190–192.
7.
Mahadeva R, Lomas DA: Genetics and respiratory disease. 2. Alpha-1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998;53:501–505.
8.
Larsson C: Natural history and life expectancy in severe alpha-1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978;204:345–351.
9.
Tobin MJ, Cook PJL, Hutchison DCS: Alpha-1-antitrypsin deficiency: The clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. Br J Dis Chest 1983;77:14–27.
10.
Janus ED, Phillips NT, Carrell RW: Smoking, lung function, and alpha-1-antitrypsin deficiency. Lancet 1985;i:152–154.
11.
Silverman EK, Miletich JP, Pierce JA, Sherman LA, Endicott SK, Broze GJ Jr, Campbell EJ: Alpha-1-antitrypsin deficiency: High prevalence in the St Louis area determined by direct population screening. Am Rev Respir Dis 1989;140:961–966.
12.
Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ: Variability of pulmonary function in alpha-1-antitrypsin deficiency: Clinical correlates. Ann Intern Med 1989;111:982–991.
13.
Silverman EK, Province MA, Campbell EJ, Pierce JA, Rao DC: Family study of alpha-1-antitrypsin deficiency: Effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits. Genet Epidemiol 1992;9:317–331.
14.
Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O’Donnell WJ, Reilly JJ, Ginns L, Mentzer S, Wain J, Speizer FE: Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770–1778.
15.
Larson RK, Barman ML, Kueppers F, Fudenberg HH: Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann Intern Med 1970;72:627–632.
16.
Cohen BH: Chronic obstructive pulmonary disease: A challenge in genetic epidemiology. Am J Epidemiol 1980;112:274–288.
17.
Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ: A family study of the variability of pulmonary function in alpha-1-antitrypsin deficiency: Quantitative phenotypes. Am Rev Respir Dis 1990;142:1015–1021.
18.
Ferris B G, Jr.: Epidemiology standardization project. Am Rev Respir Dis 1978;118:1–88.
19.
Gardner RM, Hankinson JL, Clausen JL, Crapo RO, Johnson RL Jr, Epler GR: Standardization of spirometry – 1987 update: Official statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285–1298.
20.
Crapo RO, Morris AH, Gardner RM: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659–664.
21.
Hsu KHK, Jenkins DE, Hsi BP, Bourhofer E, Thompson V, Tanakawa N, Hsieh GSJ: Ventilatory functions of normal children and young adults – Mexican-American, white, and black. I. Spirometry. J Pediatr 1979;95:14–23.
22.
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B: Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725–734.
23.
Pierce JA, Eradio BG: Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. J Lab Clin Med 1979;94:826–831.
24.
Silverman EK, Speizer FE: Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996;80:501–522.
25.
Blangero J, Almasy L: Multipoint oligogenic linkage analysis of quantitative traits. Genet Epidemiol 1997;14:959–964.
26.
Olson JM, Wijsman EM: Linkage between quantitative trait and marker loci: Methods using all relative pairs. Genet Epidemiol 1993;10:87–102.
27.
Terwilliger JD, Ott J: Handbook of Human Genetic Linkage. Baltimore, Johns Hopkins University Press, 1994.
28.
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES: Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 1996;58:1347–1363.
29.
Abreu PC, Greenberg DA, Hodge SE: Direct power comparisons between simple LOD scores and NPL scores for linkage analysis in complex diseases. Am J Hum Genet 1999;65:847–857.
30.
Lange K, Weeks D, Boehnke M: Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE (letter). Genet Epidemiol 1988;5:471–472.
31.
Davis S, Weeks DE: Comparison of nonparametric statistics for detection of linkage in nuclear families: Single-marker evaluation. Am J Hum Genet 1997;61:1431–1444.
32.
Cox DW, Woo SL, Mansfield T: DNA restriction fragments associated with alpha-1-antitrypsin indicate a single origin for deficiency allele PI Z. Nature 1985;316:79–81.
33.
Silverman EK, Province MA, Campbell EJ, Pierce JA, Rao DC: Variability of pulmonary function in alpha-1-antitrypsin deficiency: Residual family resemblance beyond the effect of the Pi locus. Hum Hered 1990;40:340–355.
34.
Weeks D, Lathrop G: Polygenic disease: Methods for mapping complex disease traits. Trends Genet 1995;11:513–519.
35.
Kong A, Cox NJ: Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 1997;61:1179–1188.
36.
Allison DB, Neale MC, Zannolli R, Schork NJ, Amos CI, Blangero J: Testing the robustness of the likelihood-ratio test in a variance-component quantitative-trait loci-mapping procedure. Am J Hum Genet 1999;65:531–544.
37.
Elston RC, Namboodiri KK, Go RC, Siervogel RM, Glueck CJ: Probable linkage between essential familial hypercholesterolemia and third complement component (C3). Birth Defects Orig Article Ser 1976;12:294–297.
38.
Lange K, Spence MA, Frank MB: Application of the lod method to the detection of linkage between a quantitative trait and a qualitative marker: A simulation experiment. Am J Hum Genet 1976;28:167–173.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.